Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

Nature

Volumn 436, Issue 7047, 2005, Pages 117-122

  Garraway, Levi A ^a,b   Widlund, Hans R ^a   Rubin, Mark A ^b   Getz, Gad ^d   Berger, Aaron J ^e   Ramaswamy, Sridhar ^d,f   Beroukhim, Rameen ^a,b   Milner, Danny A ^b   Granter, Scott R ^b   Du, Jinyan ^a,d   Lee, Charles ^b   Wagner, Stephan N ^g   Li, Cheng ^a,c   Golub, Todd R ^a,b,d   Rimm, David L ^e   Meyerson, Matthew L ^a,b,d   Fisher, David E ^a,b   Sellers, William R ^a,b,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g Universitatsklinik fur Dermatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; NUCLEIC ACIDS; PATIENT TREATMENT; TUMORS;

CANCER GENOMES; GENE EXPRESSION; GENETIC MAPS; SINGLE-NUCLEOTIDE POLYMORPHISM (SNP);

GENES;

B RAF KINASE; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; DOCETAXEL; GENE PRODUCT; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; MITF PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

MEDICINE;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RESISTANCE; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; GENE ACTIVITY; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MAPPING; GENE TARGETING; GENOME ANALYSIS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MELANOCYTE; MELANOMA; METASTASIS; MITF GENE; ONCOGENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; CELL LINEAGE; CHROMOSOME 3; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; PATHOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL LINEAGE; CELL SURVIVAL; CHROMOSOMES, HUMAN, PAIR 3; DISEASE PROGRESSION; DNA-BINDING PROTEINS; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; ONCOGENES; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSCRIPTION FACTORS;

EID: 21844478747     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03664     Document Type: Article

References (29)

1. Lindblad-Toh, K. et al. Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nature Biotechnol. 18, 1001-1005 (2000).
2. Lieberfarb, M. E. et al. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res. 63, 4781-4785 (2003).
3. Mei, R. et al. Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays. Genome Res. 10, 1126-1137 (2000).
4. Zhao, X. et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res. 64, 3060-3071 (2004).
5. Bignell, G. R. et al. High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res. 14, 287-295 (2004).
6. Stinson, S. F. et al. Morphological and immunocytochemical characteristics of human tumour cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res. 12, 1035-1053 (1992).
7. Ross, D. T. et al. Systematic variation in gene expression patterns in human cancer cell lines. Nature Genet. 24, 227-235 (2000).
8. Roschke, A. V. et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res. 63, 8634-8647 (2003).
9. Nishizuka, S. et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl Acad. Sci. USA 100, 14229-14234 (2003).
10. Monks, A., Scudiero, D. A., Johnson, G. S., Paull, K. D. & Sausville, E. A. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des. 12, 533-541 (1997).
11. Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 95, 14863-14868 (1998).
12. Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999).
13. Steingrimsson, E., Copeland, N. G. & Jenkins, N. A. Melanocytes and the Microphthalmia Transcription Factor Network. Annu. Rev. Genet. 38, 365-411 (2004).
14. Camp, R. L., Dolled-Filhart, M., King, B. L. & Rimm, D. L. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res. 63, 1445-1448 (2003).
15. Hemesath, T. J., Price, E. R., Takemoto, C., Badalian, T. & Fisher, D. E. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 391, 298-301 (1998).
16. Price, E. R. et al. Lineage-specific signalling in melanocytes. C-kit stimulation recruits p300/CBP to microphthalmia. J. Biol. Chem. 273, 17983-17986 (1998).
17. Wu, M. et al. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 14, 301-312 (2000).
18. Loercher, A. E., Tank, E. M., Delston, R. B. & Harbour, J. W. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J. Cell Biol. 168, 35-40 (2005).
19. Carreira, S. et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433, 764-769 (2005).
20. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
21. Jafari, M. et al. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J. Cancer Res. Clin. Oncol. 121, 23-30 (1995).
22. Kubo, A. et al. The p16 status of tumour cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin. Cancer Res. 5, 4279-4286 (1999).
23. McGill, G. G. et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109, 707-718 (2002).
24. Du, J. et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6, 565-576 (2004).
25. Chu, W. et al. Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. Oncogens 19, 395-402 (2000).
26. Berger, R. et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 64, 8867-8875 (2004).
27. Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nature Med. 10, 33-39 (2004).
28. Berger, A. J. et al. Automated quantitative analysis (AQUA) of HDM2 expression in malignant melanoma shows association with early stage disease and improved outcome. Cancer Res. (in the press).
29. Rubin, M. A. et al. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res. 64, 3814-3822 (2004).